Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials
AuthorRasmussen, TA; Tolstrup, M; Winckelmann, A; Ostergaard, L; Sogaard, OS
Source TitleHuman Vaccines and Immunotherapeutics
PublisherTAYLOR & FRANCIS INC
University of Melbourne Author/sRasmussen, Thomas
Document TypeJournal Article
CitationsRasmussen, T. A., Tolstrup, M., Winckelmann, A., Ostergaard, L. & Sogaard, O. S. (2013). Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 9 (4), pp.790-799. https://doi.org/10.4161/hv.23202.
Access StatusOpen Access
Combination antiretroviral therapy (cART) has transformed HIV from a deadly to a chronic disease, but HIV patients are still burdened with excess morbidity and mortality, long-term toxicities from cART, stigmatization, and insufficient access to cART worldwide. Thus, a cure for HIV would have enormous impact on society as well as the individual. As the complexity and mechanisms of HIV persistence during therapy are being unraveled, new therapeutic targets for HIV eradication are discovered. Substances that activate HIV production in the latently infected cells have recently received much attention. By turning on expression of latent HIV proviruses, reactivation strategies could contribute to the eradication HIV infection. Compounds that are currently being or soon to be tested in clinical trials are emphasized. The results from these trials will provide important clues as to whether or not reactivating strategies could become significant components of a cure for HIV.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References